The Food and Drug Administration has announced that applications for commercial distribution of Covid19 vaccines may come in as early as the end of this year or early next year.
FDA director general Dr. Eric Domingo clarified however, that one requirement of the application would be the jab completing its Phase 3 clinical trials.
Currently, only the following vaccine makers received emergency use authorization in the country: Pfizer-BioNTech, Oxford-AstraZeneca, Gamaleya Institute, Sinovac, Johnson & Johnson, Bharat Biotech and Moderna.
Sinopharm, whose jab President Rodrigo Duterte was recently inoculated with, only has a compassionate special permit, which does not allow them to make their vaccines commercially available.
Following backlash from using a non-approved vaccine, Duterte ordered the pull-out of the rest of the Sinopharm doses from the country.
“I think yesterday we were very successfully able to explain to the President the situation,” said Domingo. “And as you can see the President is maybe willing to rectify once he realize[d] there was a problem using a vaccine that is under CSP instead of [one that is] under EUA.”
The agency has requested the Presidential Security Group—some members of whom were vaccinated with Sinopharm doses last year—to submit a report indicating the number of doses that entered the country, the number used and a list of persons jabbed, as well as recorded side effects.
Photo: Business Mirror